Amylyx Pharmaceuticals, Inc. filed a Form 8-K on August 18, 2026, disclosing positive topline results from its Phase 3 LUCIDITY clinical trial evaluating avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.

Key Highlights

  • Primary endpoint met: LUCIDITY demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003).
  • All secondary endpoints met: The trial showed reductions in Level 2 events by self-monitoring of blood glucose, Level 2 events by continuous glucose monitoring, and Level 3 hypoglycemic events.
  • Trial size and design: LUCIDITY enrolled 78 adult participants, randomized 3:2 to receive 90 mg avexitide subcutaneously once daily or placebo through a 16-week double-blind period.
  • Safety profile: The majority of adverse events were mild to moderate, with no serious adverse events related to avexitide treatment and no changes in body weight observed in either group.
  • NDA submission planned: The company disclosed plans to submit a New Drug Application to the FDA by the end of 2026.
  • Breakthrough Therapy Designation: The FDA previously granted avexitide Breakthrough Therapy Designation for post-bariatric hypoglycemia, according to the filing.

Amylyx Pharmaceuticals LUCIDITY Trial Results: Avexitide in Post-Bariatric Hypoglycemia

According to the filing, LUCIDITY was a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating avexitide, described as "an investigational, first-in-class glucagon-like peptide-1 ('GLP-1') receptor antagonist," in participants with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. The trial met the FDA-agreed-upon primary endpoint, demonstrating a 55% reduction (p=0.000003) in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo through Week 16.

The filing reported that LUCIDITY also met all secondary endpoints, with "consistent, highly statistically significant, and clinically meaningful reductions" across SMBG-measured Level 2 events, CGM-measured Level 2 events, and independently adjudicated Level 3 events. The company disclosed that avexitide "was generally well-tolerated through the double-blind study period with a consistent and favorable safety profile replicated across all PBH clinical trials completed to date." The most common adverse events reported were diarrhea, injection site erythema, and injection site bruising.

Amylyx disclosed on NASDAQ:AMLX that it plans to submit an NDA to the FDA by the end of 2026. The filing also noted that LUCIDITY's 32-week open label extension remains ongoing, as does the avexitide expanded access program. The company stated it plans to present data from LUCIDITY at an upcoming medical meeting. Statements regarding NDA timing, potential regulatory approval, and commercialization are characterized in the filing as forward-looking statements subject to risks and uncertainties.

What Was Disclosed

Amylyx Pharmaceuticals filed an 8-K on August 18, 2026, under Items 7.01 and 8.01, disclosing positive topline Phase 3 results for avexitide in post-bariatric hypoglycemia and announcing plans to file an NDA with the FDA by year-end 2026.